Cogent Biosciences(US:COGT) Yahoo Finance·2026-02-17 17:58Company Overview - Cogent Biosciences is a clinical-stage biotechnology company focused on targeted therapies for genetically driven diseases, leveraging scientific expertise and strategic partnerships to develop innovative treatments for significant unmet medical needs [6] - The company has a market capitalization of $5.55 billion and reported a net income loss of $294.37 million for the trailing twelve months [4] Recent Developments - On February 13, 2026, First Turn Management disclosed a new position in Cogent Biosciences, acquiring 824,283 shares valued at $29.28 million at the end of the quarter [1][2] - As of February 13, 2026, Cogent's share price was $36.53, reflecting a 346.6% increase over the prior year, significantly outperforming the S&P 500 by 334.8 percentage points [8] Financial Position - Cogent Biosciences entered 2026 with approximately $901 million in cash and marketable securities, providing a financial runway into 2028 [12] - The company reported a full-year net loss of $328.9 million for 2025, which is typical for late-stage biotech firms, indicating execution risk [12] Product Development and Pipeline - The lead candidate focuses on KIT mutations in systemic mastocytosis and gastrointestinal stromal tumors, with a business model centered on proprietary drug development and commercialization [9] - Recent clinical data showed a median progression-free survival of 16.5 months for bezuclastinib plus sunitinib compared to 9.2 months for sunitinib alone, leading to a significant re-rating of the stock [11] Investment Implications - The new position by First Turn Management represents 3.35% of its reportable U.S. equity assets under management as of December 31, 2025, aligning with other mid-cap biotech investments [8][13] - Long-term investment thesis hinges on regulatory execution and commercial uptake expected in the second half of 2026, emphasizing the importance of durability over short-term headlines [13]